Boston area's noteworthy life science startups

Boston area is famous for its world-class universities, mature clusters of health care and life sciences The city has spawned a number of start-ups and brought them to the world stage, with a particular focus on companies in the field of life sciences In this list, which was selected by equaloocean, an information services and investment research company, there are 20 life science start-ups in Boston that deserve attention There are 17 biotechnology and medicine, 1 digital health and medical equipment, and 1 Artificial Intelligence health Twelve of these start-ups, based in Cambridge, where Harvard University and MIT are located, offer excellent opportunities for scientists, researchers and professional development The total financing of all companies on the list is more than $100 million Digital medicine mainly uses applications or platforms to digitize patients' traditional medical services It has a lot of hardware supporting devices At present, due to the wide use of mobile phones, the technology is more and more easy for users to use According to the research of grand view research, by 2027, the mobile digital medical market will reach US $316.8 billion, with a CAGR of 29.2% This market attracts companies such as pear therapeutics to provide patients with better prognosis and more intelligent clinical medical and monitoring tools Pear has a series of products and candidate products on the market, and its treatment field includes serious mental and neurological diseases Its first product is RSET for the treatment of drug abuse disorder (SUD), which is the first digital medical prescription therapy approved by FDA for the treatment of diseases Currently, the company has announced cooperation with apricity health to promote the development of digital therapy in the field of immunotherapy Medical devices range from simple, low-risk devices (such as medical thermometers and disposable gloves) to high-risk devices that implant and sustain life High risk equipment usually requires higher requirements of supervision and control According to statista's report, from 2013 to 2017, the number of medical device recalls increased from 2303 to 3202, the biggest reason being the design of medical devices Although the recall rate is not low, this huge market still attracts investors and start-ups, making the United States one of the largest medical equipment markets in the world Beta bionics, a bionic device company, stands out from many device startups Two months ago, the device Ilet developed by Ilet was recognized as a breakthrough device The device can automatically adapt to the changing insulin treatment of patients and meet the treatment needs of patients with type 1 diabetes The biomedical sector is the real trend segment in Boston Of the 20 life science startups to watch, 17 are in the field, including one called relay therapeutics This company has been listed on the industry's famous annual "fierce biotechnology's 2017 fierce 15" list The core of the company's development platform is to understand how protein conformation relates to function Its initial project focuses on the development of the next generation of cancer therapy At present, highly selective inhibitors of pathogenic proteins have been developed in the patient population defined by the genome In December 2018, it completed round C financing of 400 million US dollars The pharmaceutical sector covers a number of start-ups focused on the treatment of different diseases, such as metabolic diseases and pain management Oncologie, which is committed to the development of cancer microenvironment and innovative anti-cancer therapy, is a listed company with branches in China Last year, it reached a clinical trial cooperation agreement with MSD to evaluate the efficacy of bavituximab, an anti phosphatidylserine (PS) antibody under development, in combination with keytruda, an anti PD-1 therapy of MSD, in the treatment of advanced gastric cancer or adenocarcinoma of the esophageal gastric junction Arakis therapeutics, a biopharmaceutical company, which is widely concerned in the field of targeted RNA therapy, has developed a systematic treatment method Through computer simulation technology and high-throughput molecular biology tools, it has found and verified RNA targets that can be made into medicines Its researchers have also set up a variety of screening methods, and at present have screened hundreds of potential targets Through identifying the binding sites of targeted RNA, the molecular recognition mechanism of targeted RNA has been deduced and established They have promoted a series of new drug research and development projects for a variety of innovative RNA targets KSQ therapeutics, which established a drug discovery technology platform based on CRISPR technology, has also launched 12 drug research and development projects KSQ applied crispremics technology to T cells, screened all genes comprehensively through functional analysis, and confirmed several gene targets that could strengthen T cell therapy and drug therapy in cancer immunity The first project in KSQ R & D pipeline is a car-t-like T-cell therapy based on T-cell genome analysis This targeted T cell has been shown to have high activity against pd-1-resistant solid tumors in several animal models In addition, inozyme Pharma is studying the treatment of metabolic diseases Centrexion therapeutics aims to reduce the burden on patients with chronic pain, with a total financing of more than $182 million Another company, lyndra therapeutics, focuses on product development that reduces side effects and improves efficacy The company has announced that its products can stay in patients for a week and continue to work The focus of gene therapy is to correct or compensate for diseases caused by gene defects and abnormalities According to grand view research, the scale of gene therapy will reach 5.55 billion US dollars by 2026, with a compound annual growth rate of 33.9% The three companies on the list do well in this field The first is generation bio, whose therapy is based on its proprietary genewave technology, which can provide sustained, high-level gene expression, and can be administered repeatedly to regulate and maintain life-long treatment Because the immunogenicity of viral vector gene therapy limits the repeated dose of treatment and prevention, it overcomes the defect of viral vector gene therapy Another company, egenesis, uses gene scissor tools to reduce the rejection between different organs and the harm of different viruses, so as to promote the clinical application of xenotransplantation Three months ago, the company completed a $100 million financing to promote CRISPR pig kidney to human trials Foghorn therapeutics aims to develop new drugs targeting chromatin remodeling complexes Four companies on the list focus on cancer treatment A company called thrive early detection is developing cancerseek, a liquid biopsy that can detect multiple types of cancer early in life Recently, it has completed a total financing of $110 million Oncorus is promoting innovative oncolytic therapy Last August, the company completed nearly $80 million in financing to push an anti-cancer virus into human testing Compass therapeutics has developed an antibody candidate drug that can identify almost all targets in human immune synapses Its initial research focuses on T cells, natural killer (NK) cells and macrophages The company's unique antibody discovery and bispecific engineering platform, stitch mAbs, is a new high-throughput bispecific screening platform, which can quickly identify candidate drugs combined with a series of table positions on each target, and quickly identify collaborative bispecific activities Ribon therapeutics focuses on parp-7, a member of PARP family Rbn-2397 has been administered to the first patient in a phase 1 trial for the treatment of advanced solid tumors Its monoparp integrated technology platform plays an important role in regulating the stress response of cancer cell survival Only one AI health company on the list, Concerto healthai, is on the list The company focuses on real world data (RWD) and enterprise level AI technology solutions for precision oncology Recently, the company released eurekahealth 3.0 This is the first real world evidence (RWE) and AI technology combination solution, with speed, accuracy and credibility, which can provide high-performance RWE in-depth analysis for oncology clinical research and development in the field of life science In addition to cancer and genes, cell therapy and kidney disease therapy have also attracted the interest of start-ups Dr Armon sharei, CEO of SQZ biotech, said that 2020 will be an exciting year for SQZ, and they are about to get data from their first clinical trial Goldfinch bio is developing treatments for kidney disease Last May, it teamed up with Gilead sciences to develop innovative therapies for diabetic nephropathy and other rare kidney diseases.